Charles River Laboratories | CRL - Zinsaufwendungen Für Schuld

Aktienkurs
169.80
Täglich Wechseln
2.06 1.23%
Monatlich
2.36%
Jährlich
48.09%
Q2 Prognose
166.17




Zinsaufwendungen Für Schuld Veränderung Datum
Agilent USD 25M 2M 2025-12
Align Technology USD 2M 660K 2023-03
Bio-Rad Laboratories USD 12.3M 100K 2025-09
Bruker USD 20M 4.3M 2025-09
Cardinal Health USD 88M 8M 2025-12
Charles River Laboratories USD 23.78M 1.63M 2025-12
Cigna USD 157.92B 460K 2025-12
Concord Medical Services Hldg CNY 84.37M 32.34M 2023-06
CVS Health USD 787M 3M 2025-12
Danaher USD 63M 8M 2026-03
Dentsply International USD 22M 1000K 2025-12
Elevance Health USD 357M 9M 2026-03
Galapagos EUR 1.72M 940K 2025-09
Humana USD 146M 22M 2025-12
Illumina USD 25M 0 2025-09
Incyte USD 582K 10K 2025-12
Intrexon USD 2K 5K 2024-06
IQVIA Holdings USD 193M 4M 2025-12
Laboratory Of America USD 55M 1000K 2025-12
Lonza CHF 84M 14M 2025-06
McKesson USD 63M 11M 2025-12
Merck EUR 121M 5M 2025-12
Mettler Toledo International USD 17.39M 307K 2025-12
Novartis USD 304M 23M 2025-12
Pfizer USD 711M 59M 2025-12
Quest Diagnostics USD 69M 2M 2025-09
Revvity USD 23.51M 742K 2025-12
Thermo Fisher Scientific USD 354M 11M 2026-03
United Therapeutics USD 3.1M 100K 2025-12
UnitedHealth USD 955M 19M 2026-03
Veradigm USD 1.25M 641K 2022-09
Waters USD 8.62M 18.02M 2025-12
West Pharmaceutical Services USD 1.9M 1.7M 2026-03